Covered recipient · General Payments record
AMAR QADIR MAJJHOO
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$421,816.64
677 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $285,638.00 | 116 |
| Travel and Lodging | $64,775.97 | 136 |
| Consulting Fee | $36,718.00 | 16 |
| Honoraria | $21,036.00 | 11 |
| Food and Beverage | $13,633.98 | 394 |
| Education | $14.69 | 4 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Celgene Corporation | $124,588.55 | 104 |
| Janssen Scientific Affairs, LLC | $57,448.80 | 41 |
| Amgen Inc. | $54,983.72 | 71 |
| AbbVie, Inc. | $47,839.66 | 79 |
| Novartis Pharmaceuticals Corporation | $30,067.99 | 56 |
| Horizon Therapeutics plc | $25,138.20 | 48 |
| Lilly USA, LLC | $17,257.28 | 37 |
| Regeneron Healthcare Solutions, Inc. | $16,353.38 | 38 |
| GlaxoSmithKline, LLC. | $14,920.55 | 34 |
| Janssen Biotech, Inc. | $14,548.66 | 41 |
| PFIZER INC. | $7,600.77 | 47 |
| E.R. Squibb & Sons, L.L.C. | $6,650.60 | 28 |
| UCB, Inc. | $2,874.98 | 15 |
| Mallinckrodt Enterprises LLC | $924.84 | 6 |
| Genentech USA, Inc. | $128.57 | 11 |
| Flexion Therapeutics, Inc. | $123.00 | 7 |
| Johnson & Johnson Health Care Systems Inc. | $112.37 | 2 |
| DePuy Synthes Sales Inc. | $72.63 | 1 |
| Hikma Pharmaceuticals USA | $25.26 | 2 |
| Sebela Pharmaceuticals Inc. | $25.26 | 2 |
| Antares Pharma, Inc. | $24.01 | 1 |
| FIDIA PHARMA USA INC. | $21.75 | 1 |
| GENZYME CORPORATION | $20.27 | 1 |
| Sobi, Inc | $17.26 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17.01 | 1 |
| Merck Sharp & Dohme Corporation | $16.16 | 1 |
| SANOFI-AVENTIS U.S. LLC | $15.11 | 1 |
Page 6 of 14; records 251–300 of 677 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
AMAR QADIR MAJJHOO
NPI 1255411039 · CMS profile ID 284104
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
SAINT CLAIR SHORES, MI
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 6 of 14; records 251–300 of 677 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1255411039?year=2019&recipient=provider&page=6#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- AMAR QADIR MAJJHOO, NPI 1255411039, CMS profile ID 284104. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 14; records 251–300 of 677 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255411039?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). AMAR QADIR MAJJHOO, NPI 1255411039, CMS profile ID 284104. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 14; records 251–300 of 677 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255411039?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- AMAR QADIR MAJJHOO, NPI 1255411039, CMS profile ID 284104, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 14; records 251–300 of 677 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1255411039?year=2019&recipient=provider&page=6#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
677 matching records · $421,816.64 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 251–300 of 677.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | $546.00 | 08/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662167551 | CMS |
| Janssen Biotech, Inc. | $2,000.00 | 08/27/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658572243 | CMS |
| Janssen Biotech, Inc. | $1,500.00 | 08/27/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658572247 | CMS |
| Amgen Inc. | $121.24 | 08/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662167545 | CMS |
| Janssen Biotech, Inc. | $12.14 | 08/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658572241 | CMS |
| Janssen Scientific Affairs, LLC | $49.56 | 08/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657600987 | CMS |
| Janssen Scientific Affairs, LLC | $28.57 | 08/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657600989 | CMS |
| Janssen Scientific Affairs, LLC | $34.11 | 08/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657600991 | CMS |
| Janssen Biotech, Inc. | $1,078.86 | 08/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658572227 | CMS |
| Janssen Biotech, Inc. | $29.32 | 08/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658572231 | CMS |
| Janssen Biotech, Inc. | $34.07 | 08/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658572235 | CMS |
| Janssen Biotech, Inc. | $49.99 | 08/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658572237 | CMS |
| Janssen Scientific Affairs, LLC | $124.73 | 08/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657600985 | CMS |
| PFIZER INC. | $10.91 | 08/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673775207 | CMS |
| PFIZER INC. | $1.79 | 08/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673272449 | CMS |
| PFIZER INC. | $0.66 | 08/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673748125 | CMS |
| Regeneron Healthcare Solutions, Inc. | $16.20 | 08/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673427669 | CMS |
| AbbVie, Inc. | $23.07 | 08/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647924899 | CMS |
| AbbVie, Inc. | $3,600.00 | 08/20/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647924991 | CMS |
| AbbVie, Inc. | $29.65 | 08/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647924993 | CMS |
| AbbVie, Inc. | $48.00 | 08/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647924995 | CMS |
| AbbVie, Inc. | $46.52 | 08/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647924997 | CMS |
| Lilly USA, LLC | $1.00 | 08/19/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657668111 | CMS |
| Celgene Corporation | $4,163.00 | 08/17/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672902977 | CMS |
| Celgene Corporation | $55.00 | 08/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672980599 | CMS |
| Celgene Corporation | $40.00 | 08/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672981753 | CMS |
| Celgene Corporation | $30.00 | 08/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672987151 | CMS |
| Celgene Corporation | $169.86 | 08/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673033527 | CMS |
| Celgene Corporation | $30.00 | 08/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673033879 | CMS |
| AbbVie, Inc. | $237.60 | 08/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647924949 | CMS |
| Sobi, Inc | $17.26 | 08/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698095473 | CMS |
| Genentech USA, Inc. | $14.23 | 08/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681143759 | CMS |
| Janssen Biotech, Inc. | $9.69 | 08/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658572223 | CMS |
| Lilly USA, LLC | $15.93 | 08/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657668859 | CMS |
| AbbVie, Inc. | $25.00 | 08/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647924975 | CMS |
| AbbVie, Inc. | $20.99 | 08/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647924979 | CMS |
| AbbVie, Inc. | $421.47 | 08/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647924981 | CMS |
| AbbVie, Inc. | $45.00 | 08/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647924983 | CMS |
| AbbVie, Inc. | $25.00 | 08/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647924985 | CMS |
| AbbVie, Inc. | $67.37 | 08/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647924987 | CMS |
| PFIZER INC. | $1.86 | 08/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673276107 | CMS |
| AbbVie, Inc. | $204.06 | 08/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647924977 | CMS |
| AbbVie, Inc. | $101.45 | 08/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647924989 | CMS |
| AbbVie, Inc. | $4,000.00 | 08/07/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647924955 | CMS |
| Amgen Inc. | $15.21 | 08/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662167457 | CMS |
| Novartis Pharmaceuticals Corporation | $3.82 | 08/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659762871 | CMS |
| PFIZER INC. | $1.53 | 08/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673271745 | CMS |
| UCB, Inc. | $16.10 | 08/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688303461 | CMS |
| Horizon Therapeutics plc | $19.46 | 08/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691436205 | CMS |
| Celgene Corporation | $390.00 | 08/01/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672955393 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $5,207,473.49 | 42 |
| PY2024 | Principal investigator | $1,602,433.50 | 17 |
| PY2023 | Principal investigator | $94,249.00 | 14 |
| PY2022 | Principal investigator | $41,346.00 | 11 |
| PY2021 | Recipient | $780.00 | 1 |
| PY2021 | Principal investigator | $33,651.06 | 12 |
| PY2020 | Recipient | $3,200.00 | 1 |
| PY2020 | Principal investigator | $251,400.56 | 37 |
| PY2019 | Recipient | $3,141.67 | 1 |
| PY2019 | Principal investigator | $37,437.13 | 14 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
42 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $735.00 | 12/29/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175318416 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,350.00 | 12/26/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318270 |
| Principal investigator 1 | Janssen Research & Development, LLC | $145.00 | 12/26/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318341 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,330.00 | 12/22/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318261 |
| Principal investigator 1 | Janssen Research & Development, LLC | $360.00 | 12/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175318387 |
| Principal investigator 1 | Janssen Research & Development, LLC | $735.00 | 11/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175318393 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,700.00 | 11/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175318400 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,939.00 | 11/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175318410 |
| Principal investigator 1 | Janssen Research & Development, LLC | $448.00 | 11/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175318422 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,165.00 | 11/06/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318191 |
| Principal investigator 1 | Janssen Research & Development, LLC | $310.00 | 11/06/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318289 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,825.00 | 11/03/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318253 |
| Principal investigator 1 | AstraZeneca UK Limited | $5,598.00 | 10/20/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC | A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment | No dispute reported | 06/30/2026 | 1185537928 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35.00 | 09/08/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318230 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,840.00 | 09/08/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318303 |
| Principal investigator 1 | Janssen Research & Development, LLC | $180.00 | 08/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318347 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35.00 | 08/11/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318320 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,120.00 | 08/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318215 |
| Principal investigator 1 | Amgen Inc. | $2,782.16 | 07/28/2025 | Non-covered Recipient Entity SHORES RHEUMATOLOGY PC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246648147 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35.00 | 07/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318335 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,725.00 | 07/04/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318246 |
| Principal investigator 1 | Eli Lilly and Company | $17,309.00 | 07/01/2025 | Non-covered Recipient Entity HENRY FORD MACOMB HEALTH CENTER | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE | No dispute reported | 06/30/2026 | 1187883396 |
| Principal investigator 1 | Janssen Research & Development, LLC | $180.00 | 06/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318311 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,330.00 | 06/20/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318356 |
| Principal investigator 1 | Janssen Research & Development, LLC | $325.00 | 05/29/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318295 |
| Principal investigator 1 | Janssen Research & Development, LLC | $345.00 | 05/29/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318328 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,300.00 | 05/26/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318198 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35.00 | 05/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318372 |
| Principal investigator 1 | Janssen Research & Development, LLC | $325.00 | 04/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318238 |
| Principal investigator 1 | Amgen Inc. | $76,764.29 | 04/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC | A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) | No dispute reported | 06/30/2026 | 1246640319 |
| Principal investigator 1 | Amgen Inc. | $59,960.67 | 04/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246640321 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35.00 | 03/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318225 |
| Principal investigator 1 | Janssen Research & Development, LLC | $325.00 | 03/03/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318206 |
| Principal investigator 1 | Amgen Inc. | $22,804.47 | 02/20/2025 | Non-covered Recipient Entity SHORES RHEUMATOLOGY | A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) | No dispute reported | 06/30/2026 | 1246648151 |
| Principal investigator 1 | Amgen Inc. | $60,251.78 | 02/19/2025 | Non-covered Recipient Entity SHORES RHEUMATOLOGY | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246648154 |
| Principal investigator 1 | Amgen Inc. | $12,983.74 | 01/28/2025 | Non-covered Recipient Entity STAT RESEARCH | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246648708 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 01/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175318380 |
| Principal investigator 1 | Amgen Inc. | $9,700.17 | 01/13/2025 | Non-covered Recipient Entity BRADENTON RESEARCH CENTER | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246639781 |
| Principal investigator 1 | AstraZeneca UK Limited | $2,206.00 | 01/13/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICHIGAN, LLC | A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment | No dispute reported | 06/30/2026 | 1185537930 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.00 | 01/07/2025 | Non-covered Recipient Entity Clnc Rsrch Inst Of Michigan Llc | A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) | No dispute reported | 06/30/2026 | 1175231797 |
| Principal investigator 1 | Amgen Inc. | $11,604.05 | 01/03/2025 | Non-covered Recipient Entity SHORES RHEUMATOLOGY | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246648167 |
| Principal investigator 1 | Amgen Inc. | $4,839,047.16 | 01/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC | A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants | No dispute reported | 06/30/2026 | 1246640323 |